OOIR: Observatory of International Research

Papers

(The H4-Index of npj Parkinsons Disease is 42. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Effects of Alzheimer’s genetic risk scores and CSF biomarkers in de novo Parkinson’s Disease	165
Gait abnormalities and non-motor symptoms predict abnormal dopaminergic imaging in presumed drug-induced Parkinsonism	108
Cdk5 phosphorylation-induced SIRT2 nuclear translocation promotes the death of dopaminergic neurons in Parkinson’s disease	102
Author Correction: Enteric α-synuclein impairs intestinal epithelial barrier through caspase-1-inflammasome signaling in Parkinson’s disease before brain pathology	101
Author Correction: Synaptic loss and its association with symptom severity in Parkinson’s disease	90
Patient-centered development of clinical outcome assessments in early Parkinson disease: key priorities and advances	88
Push-pull effects of basal ganglia network in Parkinson’s disease inferred by functional MRI	86
VisionMD: an open-source tool for video-based analysis of motor function in movement disorders	84
Differences in brain aging between sexes in Parkinson’s disease	82
Cell-to-cell transmitted alpha-synuclein recapitulates experimental Parkinson’s disease	82
Alpha synuclein modulates mitochondrial Ca2+ uptake from ER during cell stimulation and under stress conditions	80
Reference SVA insertion polymorphisms are associated with Parkinson’s Disease progression and differential gene expression	80
Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson’s disease	80
CSF α-synuclein seed amplification kinetic profiles are associated with cognitive decline in Parkinson’s disease	75
Irisin exhibits neuroprotection by preventing mitochondrial damage in Parkinson’s disease	73
Advanced brain aging in Parkinson’s disease with cognitive impairment	70
Redefining the hypotheses driving Parkinson’s diseases research	69
Patterns of cerebellar cortex hypermetabolism on motor and cognitive functions in PD	66
A systematic exploration of unexploited genes for oxidative stress in Parkinson’s disease	66
Machine Learning in the Parkinson’s disease smartwatch (PADS) dataset	63
A versatile computational algorithm for time-series data analysis and machine-learning models	62
Unveiling early signs of Parkinson’s disease via a longitudinal analysis of celebrity speech recordings	56
α-Synuclein aggregation in the olfactory bulb induces olfactory deficits by perturbing granule cells and granular–mitral synaptic transmission	55
Balance response to levodopa predicts balance improvement after bilateral subthalamic nucleus deep brain stimulation in Parkinson’s disease	55
Anxiety in synucleinopathies: neuronal circuitry, underlying pathomechanisms and current therapeutic strategies	54

The experience of Anxiety for people with Parkinson’s disease	53
Park7 deletion leads to sex-specific transcriptome changes involving NRF2-CYP1B1 axis in mouse midbrain astrocytes	52
Immunological shifts during early-stage Parkinson’s disease identified with DNA methylation data on longitudinally collected blood samples	52
Plasma GFAP as a prognostic biomarker of motor subtype in early Parkinson’s disease	50
Cerebrospinal fluid biomarkers in Parkinson’s disease with freezing of gait: an exploratory analysis	50
A systematic review and meta-analysis of the prevalence of Parkinson’s disease in lower to upper-middle-income countries	50
Identification of PLOD3 and LRRN3 as potential biomarkers for Parkinson’s disease based on integrative analysis	49
C/EBPβ/AEP is age-dependently activated in Parkinson’s disease and mediates α-synuclein in the gut and brain	49
Parkinson’s disease clinical milestones and mortality	48
Mechanisms of peripheral levodopa resistance in Parkinson’s disease	47
A skin-specific α-Synuclein seeding amplification assay for diagnosing Parkinson’s disease	45
Synuclein phosphorylation: pathogenic or physiologic?	45
Tau seeding activity in skin biopsy differentiates tauopathies from synucleinopathies	45
Diurnal modulation of subthalamic beta oscillatory power in Parkinson’s disease patients during deep brain stimulation	44
Gaps and roadmap of novel neuromodulation targets for treatment of gait in Parkinson’s disease	44
Impaired migratory phenotype of CD4+ T cells in Parkinson’s disease	44
Prodromal Parkinson’s disease and subsequent risk of Parkinson’s disease and mortality	43
Reply to Matters Arising: Is congenital anosmia protective for Parkinson’s disease triggered by pathogenic entrance through the nose?	42
Does Black vs. White race affect practitioners’ appraisal of Parkinson’s disease?	42
Identification of cerebrospinal fluid biomarkers for parkinsonism using a proteomics approach	42